- Five Prime Therapeutics (NASDAQ:FPRX): Q1 GAAP EPS of -$0.57 beats by $0.11.
- More news on: Five Prime Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Five Prime Therapeutics Inc. Company Name:
FPRX Stock Symbol:
Market:
Five Prime Therapeutics Inc. Website:
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all out...
Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live , recorded on ...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the co...